Copyright © 2001 by the European Society of Cardiology.
Letter to the Editors
About EMIP-FR and reperfusion damage in AMI: a comment to the comment
Cardiothoracic Department, Institute of Clinical Physiology (CNR), University of Pisa, Pisa, Italy
References
- Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580–588
[Abstract/Free Full Text] - Harpey C, Clauser P, Labrid C, Freyria JL, Poirier JP. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev. 1988;6:212–292
- Maridonneau-Parini I, Harpey C. Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red blood cells. Br J Clin Pharmacol. 1985;20:148–151[ISI][Medline]
- Kober G, Buck T, Sievert H, Vallbracht. Myocardial protection during percutaneous transluminal coronary angioplasty: effect of trimetazidine. Eur Heart J. 1992;13:1109–1115
[Abstract/Free Full Text] - Fabiani JN, Ponzio O, Emerit I. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg. 1992;33:486–491[Medline]
- Eur Heart J. 2000;21:1537–1546
[Abstract/Free Full Text] - Gech ED, Dodd NJ, Jackson MJ. Evidence for free radical generation after primary percutaneous transluminal angioplasty recanalization in acute myocardial infarction. Am J Cardiol. 1996;77:1227
- Brodie BR, Stuckey TD, Wall TC. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1998;32:1312–1319
[Abstract/Free Full Text] - Chareonthaitawee P, Gibbons RJ, Roberts RS. The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. Heart. 2000;84:142–148
[Abstract/Free Full Text] - Tognoni G. The EMIP Project. Eur Heart J. 2000;21:1498–1499
[Free Full Text] - Kloner RA, Bolli R, Marban E. Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. Circulation. 1998;97:1848–1867
[Free Full Text] - Ito H, Maruyama A, Iwakura K. Clinical implications of the ‘no-reflow-phenomenon. A predictor of complications and left ventricular remodelling in reperfused anterior wall myocardial infarction. Circulation. 1996;93:223–228
[Abstract/Free Full Text] - Morishima I, Sone T, Mokuno S. Clinical significance of no-reflow phenomenon observed on angiography after successful treatment of acute myocardial infarction with percutaneous transluminal angioplasty. Am Heart J. 1995;130:239–243[CrossRef][ISI][Medline]
- Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest. 1985;76:1713–1719[ISI][Medline]
- Marzilli M, Mariani M. Acute myocardial infarction: new protagonists and new challenges. Eur heart J. 1999;20:1691–1692
[Free Full Text] - Theroux P. Myocardial cell protection. A challenging time for action and a challenging time for clinical research. Circulation. 2000;101:2874–2876
[Free Full Text] - Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101:2154–2159
[Abstract/Free Full Text] - Mahaffey KW, Puma JA, Barbagelata A. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 1991;34:1711–1720
- Karila-Cohen D, Czitrom D, Brochet E. Decreased no-reflow in patients with anterior myocardial infarction and pre-infarction angina. Eur Heart J. 1999;20:1724–1730
[Abstract/Free Full Text] - Rupprecht HJ, vom Dahl J, Terres W. Protective effects of the Na/H exchange inhibitor cariporide in patients with anterior myocardial infarction undergoing direct PTCA. Circulation. 2000;101:2902–2908
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||